Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997-2017).
Beltrán-Pavez C, Gutiérrez-López M, Rubio-Garrido M, Valadés-Alcaraz A, Prieto L, Ramos JT, Jiménez De Ory S, Navarro M, Díez-Romero C, Pulido F, Valencia E, Holguín Á; Madrid Cohort of HIV-Infected Children integrated in the Pediatric Branch of the Spanish National AIDS Network (CoRISpe). Beltrán-Pavez C, et al. Among authors: valencia e. Sci Rep. 2020 Oct 9;10(1):16891. doi: 10.1038/s41598-020-70861-x. Sci Rep. 2020. PMID: 33037235 Free PMC article.
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Bendala-Estrada AD, Diaz-Almiron M, Busca C, Mican R, Cadiñanos J, Montes ML, Martin-Carbonero L, Valencia E, Montejano R, Delgado-Hierro A, Bernardino JI. Bendala-Estrada AD, et al. Among authors: valencia e. HIV Med. 2023 May;24(5):558-567. doi: 10.1111/hiv.13432. Epub 2022 Nov 16. HIV Med. 2023. PMID: 36394195
Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study.
Palmier E, De Miguel R, Montejano R, Busca C, Micán R, Ramos L, Cadiñanos J, Serrano L, Bernardino JI, Pérez-Valero I, Valencia E, Arribas JR, Montes ML, González-García J, Martín-Carbonero L. Palmier E, et al. Among authors: valencia e. HIV Med. 2023 Sep;24(9):1013-1019. doi: 10.1111/hiv.13500. Epub 2023 May 16. HIV Med. 2023. PMID: 37194419
Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study.
Busca-Arenzana C, Ortega-González D, Díaz-Almirón M, Montes ML, Martin-Carbonero L, Mican R, Montejano R, Ramos-Ruperto L, Valencia E, Delgado-Hierro A, Bernardino JI. Busca-Arenzana C, et al. Among authors: valencia e. HIV Med. 2024 Sep;25(9):1030-1039. doi: 10.1111/hiv.13659. Epub 2024 May 15. HIV Med. 2024. PMID: 38746980
Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD.
Moragrega ÁB, Busca C, Apostolova N, Olveira A, Martín-Carbonero L, Valencia E, Moreno V, Bernardino JI, Abadía M, González-García J, Esplugues JV, Montes ML, Blas-García A. Moragrega ÁB, et al. Among authors: valencia e. Biomedicines. 2024 Jun 29;12(7):1454. doi: 10.3390/biomedicines12071454. Biomedicines. 2024. PMID: 39062027 Free PMC article.
Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain.
Izquierdo R, Suárez-García I, Gómez-García T, Marco-Sánchez C, Puente-Ferreiro J, Moreno C, Diaz A, Cabello-Clotet N, Vinuesa D, Blanco JL, Melús E, Gómez-Ayerbe C, Olalla J, Riera M, Bernardino JI, de López Bernaldo de Quirós JC, Moreno S, Jarrín I; CoRIS cohort. Izquierdo R, et al. HIV Med. 2024 Oct 25. doi: 10.1111/hiv.13726. Online ahead of print. HIV Med. 2024. PMID: 39455423
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masiá M, Fanciulli C, Hernández C, Lagarde M, Gutierrez A, Curran A, Morano L, Montero-Alonso M, Troya J, Rigo R, Casadellà M, Navarro-Alcaraz A, Ardila F, Parera M, Bernal E, Echeverria P, Estrada V, Hidalgo-Tenorio C, Macias J, Prieto P, Portilla J, Valencia E, Vivancos MJ, Rivero A. Podzamczer D, et al. Among authors: valencia e. J Antimicrob Chemother. 2023 Nov 6;78(11):2696-2701. doi: 10.1093/jac/dkad285. J Antimicrob Chemother. 2023. PMID: 37725999 Clinical Trial.
368 results